Walmart Covers Ozempic, Mounjaro Free for Employees With Diabetes
Walmart expands worker benefits to include GLP-1 drugs, inhalers, and insulin at zero cost after prior authorization approval.
Walmart just made a big move for its workforce. The retail giant is rolling out zero-cost coverage for GLP-1 medications — including Novo Nordisk's Ozempic and Eli Lilly's Mounjaro — specifically for employees diagnosed with Type 2 diabetes. The catch: workers need to clear a prior authorization hurdle first. Clear it, and the drugs are free.
This matters beyond the break room. Walmart employs roughly 1.6 million people in the US, making it one of the largest private employers in the country. When a company this size shifts its benefits structure, it sends a signal to every other major employer watching from the sidelines. Expect copycat moves.
Read more Salesforce Acquires AI Analytics Platform Loops →
The benefit expansion doesn't stop at GLP-1s. Walmart is also folding in inhalers and insulin at no cost to employees. That's a direct hit on out-of-pocket costs that have historically crushed lower-income workers — exactly the demographic that makes up a huge chunk of Walmart's staff.
For traders, this is a read on the GLP-1 demand story. Employer-sponsored coverage is one of the biggest unlocks for Ozempic and Mounjaro adoption at scale. Every Fortune 500 HR department that follows Walmart's lead puts more volume through Novo and Lilly's pipelines. Watch how both stocks respond to employer benefit announcements going forward — this is now a catalyst category.
Bottom line: Walmart is betting that subsidizing these drugs upfront reduces long-term healthcare costs for the company. It's a calculated play, not charity. Continue reading at US Top News and Analysis.
